Radiotherapy alone remains standard for early-stage cervical cancer

A recent clinical trial, NRG Oncology GOG-0263, found that adding cisplatin-based chemotherapy to radiotherapy after surgery for early-stage cervical cancer did not improve patient outcomes. Instead, it increased toxicity. The trial involved 316 patients who underwent radical hysterectomy. They were randomly assigned to receive either chemotherapy with radiotherapy or radiotherapy alone. The results showed similar recurrence-free survival rates for both groups, with more severe side effects in the chemotherapy group. These findings support the current standard of care, which is radiotherapy alone after surgery. Future research may explore different chemotherapy timing or alternatives to improve outcomes while reducing side effects.